A patient with HFrEF is taking an ARNI, evidence-based beta blocker and MRA but has not received an SGLT2 inhibitor. eGFR and volume status are suitab...

Question

A patient with HFrEF is taking an ARNI, evidence-based beta blocker and MRA but has not received an SGLT2 inhibitor. eGFR and volume status are suitable. Which addition completes the core disease-modifying combination?

Accepted Answer

An SGLT2 inhibitor

Answer

Ivabradine

Answer

Digoxin

Answer

A long-acting nitrate

Answer

A non-dihydropyridine calcium-channel blocker

Heart Failure (HFrEF) — MRCP Part 1 MCQ

A patient with HFrEF is taking an ARNI, evidence-based beta blocker and MRA but has not received an SGLT2 inhibitor. eGFR and volume status are suitable. Which addition completes the core disease-modifying combination?